Natural Phenomenon or Process
Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs
Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development
Kronos Undergoes Major Restructuring: CEO Norbert Bischofberger Exits Amid 83% Workforce Reduction
Kronos layoffs, Norbert Bischofberger, biotech industry, workforce reduction, restructuring
Biopharma Companies Continue Layoffs: Novartis, Recursion, and Kronos Reduce Staff Amid Industry Restructuring
Biopharma layoffs, Novartis restructuring, Recursion, Kronos, pharmaceutical industry, workforce reduction, cost-cutting measures
AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback
AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).
AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion
AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)
Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events
Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction
Gilead Sciences Announces Layoffs at California HQ and Closure of Seattle Office
Gilead Sciences, layoffs, California HQ, Seattle office closure, biopharma, workforce reduction
Sensei Biotherapeutics Announces Major Restructuring: 46% Workforce Reduction and Closure of Rockville Research Site
Sensei Biotherapeutics, workforce reduction, research site closure, organizational restructuring, SNS-101 clinical development
Marinus Pharmaceuticals Cuts 45% of Workforce Following Clinical Setbacks
Marinus Pharmaceuticals, layoffs, workforce reduction, clinical setbacks, ganaxolone, seizures, tuberous sclerosis complex (TSC), refractory status epilepticus (RSE)
FDA Authorizes LumiThera’s Valeda Light Delivery System for Dry AMD Treatment
FDA authorization, Valeda Light Delivery System, dry AMD treatment, photobiomodulation, LumiThera